Article Sidebar
Published:
Nov 19, 2024Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Efficacy of bivalent, quadrivalent and nonavalent vaccines against human papillomavirus and cervical intraepithelial lesions: A systematic review
Abstract
Purpose: To investigate the effectiveness of bivalent (2v), quadrivalent (4v) and nonavalent (9v) vaccines against human papillomavirus (HPV) and cervical intraepithelial neoplasia (CIN). Methods: This review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria and involved an electronic search of studies published from 2018 to 2023. The efficacy of each vaccine was evaluated by comparing the number of vaccinated individuals with the number of positive cases using a 95 % confidence interval (CI). Results: The overall effectiveness of the 2v, 4v and 9v vaccines against CIN was 87.23 %, 99.85 and 97.7 %, respectively. Based on 95 % CIs, the vaccine efficacies for CIN 1, CIN 2, CIN 3 and > 6 months of persistent infection were 87.4, 86.2, 88.08 and 95.92 % for the 2v vaccine; 99.56, 100, 100 and 75.9 % for the 4v vaccine; and 98, 96.3, 99 and 96 % for the 9v vaccine, respectively. The 4vHPV vaccine was the most effective against HPV types in terms of protection against different stages of CIN. However, the 9vHPV vaccine was highly effective and offered protection against most HPV types. Conclusion: The 9vHPV vaccine is highly effective and thus an ideal choice for HPV and CIN as it offers protection against most HPV types.
